Celularity Inc. Class A CELU 深 沪
已收盘 05-22 16:00:00 美东时间
0.8701
-0.028
-3.17%
华盛通- 最 高0.9189
- 今 开0.88
- 成交量 12.09万股
- 最 低 0.845
- 昨 收 0.8986
- 总市值 2518.59万
- 52周最高 4.35
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 0.7101
- 委 比 -54.21%
- 总股本 2894.60万
- 历史最高 134.00
- 量 比 0.84
- 振 幅 8.22%
- 历史最低 0.7101
- 每 手 1
- 风险率 0.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股夜盘 | Cabaletta Bio涨17.35%，Freshpet Inc涨16.04%
阿卡迪亚医疗保健涨-14.11%；Akanda Corp涨-10.28%；联掌门户涨-9.43%
05-04 08:05
Celularity Receives Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc. (NASDAQ:CELU) (the "Company"), a longevity-focused regenerative and cellular medicine company, today announced that on April 16, 2026, the Company received notification from the Listing Qualifications
04-18 04:38
Celularity Signs $35M Agreements For Its Placental-Derived Biomaterials Portfolio
Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a
03-10 20:32
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
NexGel to acquire Celularity biomaterial products, a deal expected to triple revenue to $35 million and make the company profitable.
03-10 20:30
Celularity Receives $12.2M In Net Cash Proceeds From Sale Of ~$126.3M Of Unused New Jersey NOLs And $1.9M Of Unused New Jersey R&D Tax Credits
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of
02-10 21:43
Celularity Files Prospectus For The Offering Of Up To 14.1M Shares Of Class A Common Stock
Celularity Inc. Up to 14,078,938 shares of Class A Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the "Selling Stockholders") are offering on a resale basis an aggregate
01-01 05:19
FDA Issues Warning Letter To Celularity Over Interfyl Marketing Claims; Co Says No Impact On Manufacturing Or Shipments
On December 1, 2025, Celularity Inc., (the "Company") received a warning letter (the "Letter") from the U.S. Food and Drug Administration (the "FDA"). The Letter relates to the use of certain marketing material for
2025-12-06 05:36
Celularity Files For 6M Series A Convertible Preferred Stock, Raising Up To $6.67M In Private Placement With Warrants
Private Placement Transaction On October 24, 2025, Celularity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "Investor"), pursuant to
2025-10-28 21:40
